CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology..

马萨诸塞州剑桥市，2024年5月22日/PRNewswire/--Nona Biosciences是一家全球生物技术公司，提供从“Idea到IND”（I到ITM）的全面解决方案，范围从目标验证和抗体发现到临床前研究，今天宣布已与阿斯利康（LSE/STO/Nasdaq:AZN）签订了临床前单克隆抗体许可协议，该抗体将用于在肿瘤学中创建靶向治疗。。

Under the terms of the agreement, Nona Biosciences shall receive US$19 million upon completion of the transaction. Nona is eligible to receive an additional US$10 million in potential near-term milestone payments and up to US$575 million upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales.

根据协议条款，Nona Biosciences在交易完成后将获得1900万美元。Nona有资格获得额外的1000万美元潜在的近期里程碑付款，并在实现特定的开发、监管和商业里程碑以及净销售额的分层版税付款后，获得高达5.75亿美元的额外款项。

In addition, Nona is eligible to receive payments for the option programs should AstraZeneca exercise these options..

此外，如果阿斯利康行使这些期权，Nona有资格获得期权计划的付款。。

'We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumor targeted therapies, to maximize the potential of our novel antibodies,' said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. 'This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients.'.

Nona Biosciences董事长王劲松（Jingsong Wang）医学博士说，我们很高兴宣布与阿斯利康（AstraZeneca）达成协议，阿斯利康是开发肿瘤靶向治疗的全球领导者，以最大限度地发挥我们新型抗体的潜力该协议进一步验证了我们领先的抗体发现平台，我们期待着看到我们的抗体发展成为癌症患者的潜在新药。”。

Puja Sapra, Senior Vice President, Tumour Targeted Delivery, Oncology R&D, AstraZeneca, said: 'The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona's innovative biologics discovery engine into novel tumor targeted therapies using AstraZeneca's industry-leading capabilities.'.

阿斯利康肿瘤研发部肿瘤靶向递送高级副总裁Puja Sapra说：“与Nona Biosciences的全球许可协议是一个令人兴奋的机会，可以利用阿斯利康行业领先的能力，将这些源自Nona创新生物制剂发现引擎的抗体进一步开发成新型肿瘤靶向疗法。”。

About Nona Biosciences

诺纳生物科学

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research.

Nona Biosciences（HBM Holdings Limited的全资子公司，香港交易所：02142）是一家致力于尖端技术创新的全球生物技术公司，提供从“Idea到IND”（I到ITM）的整体解决方案，范围从目标验证和抗体发现到临床前研究。

The integrated antibody discovery services range from antigen preparation, animal immunization, highly robust antibody screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® technology and the experienced therapeutic antibody discovery team..

综合抗体发现服务的范围从抗原制备，动物免疫，高度稳健的抗体筛选，到抗体铅的产生和工程，可开发性评估和药理学评估，利用Harbour Mice®技术和经验丰富的治疗性抗体发现团队的优势。。

Harbour Mice® generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. Integrating Harbour Mice® with highly robust antibody screening platforms, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs.

Harbour Mice®以传统的双重链和双轻链（H2L2）形式以及仅重链（HCAb）形式产生全人单克隆抗体。Nona Biosciences将Harbor Mice®与高度强大的抗体筛选平台相结合，专注于推动全球下一代转化药物的发明。

For more information, please visit www.nonabio.com and follow us on LinkedIn..

欲了解更多信息，请访问www.nonabio.com并在LinkedIn上关注我们。。

View original content:https://www.prnewswire.com/news-releases/nona-biosciences-announces-global-license-and-option-agreement-with-astrazeneca-for-monoclonal-antibody-to-be-developed-into-novel-tumor-targeted-therapies-302153513.html

查看原始内容：https://www.prnewswire.com/news-releases/nona-biosciences-announces-global-license-and-option-agreement-with-astrazeneca-for-monoclonal-antibody-to-be-developed-into-novel-tumor-targeted-therapies-302153513.html

SOURCE Nona Biosciences

SOURCE诺纳生物科学

Company Codes: HongKong:2142

公司代码：香港：2142